Considering the crucial effect of CCL5/CCR5 on the response to cisplatin treatment, we repurpose CCR5 antagonist maraviroc to enhance the chemotherapeutic efficacy of NEPC and observe a remarkable improvement in tumor suppression in the NEPC mouse model. Here, CCL5 is linked to neoplasm.